Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund Sentiment Is Stagnant On Enzymotec Ltd (ENZY)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in these filings, which are based on their September 30 holdings, data that is available nowhere else. Should you consider Enzymotec Ltd (NASDAQ:ENZY) for your portfolio? We’ll look to this invaluable collective wisdom for the answer.

Enzymotec Ltd (NASDAQ:ENZY) shares haven’t seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 5 hedge funds’ portfolios at the end of September. It is important to note that the shares of Enzymotec Ltd (NASDAQ:ENZY) were up 8.38% during the last quarter. A positive trading atmosphere during the quarter might appear contradictory against the hedge fund inactivity, prompting us to cover hedge funds with stakes in Enzymotec Ltd (NASDAQ:ENZY) at the end of the last quarter.

At the end of this article, we will also compare Enzymotec Ltd (NASDAQ:ENZY) to other stocks, including Bonanza Creek Energy Inc (NYSE:BCEI), Xerium Technologies, Inc. (NYSE:XRM), and Utah Medical Products, Inc. (NASDAQ:UTMD) to get a better sense of its popularity.

If you’d ask most traders, hedge funds are perceived as underperforming, outdated investment tools of years past. While there are greater than 8000 funds with their doors open today, Our experts look at the elite of this club, about 700 funds. These hedge fund managers orchestrate the lion’s share of the smart money’s total capital, and by watching their finest stock picks, Insider Monkey has discovered many investment strategies that have historically outperformed the market. Insider Monkey’s small-cap hedge fund strategy outpaced the S&P 500 index by 12 percentage points annually for a decade in their back tests.

Keeping this in mind, let’s take a peek at the recent action surrounding Enzymotec Ltd (NASDAQ:ENZY).

What does the smart money think about Enzymotec Ltd (NASDAQ:ENZY)?

At the end of the third quarter, a total of 5 of the hedge funds tracked by Insider Monkey were long this stock, a unchanged from one quarter earlier. With hedgies’ capital changing hands, there exists a select group of noteworthy hedge fund managers who were upping their stakes meaningfully (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, John Paulson’s Paulson & Co has the biggest position in Enzymotec Ltd (NASDAQ:ENZY), worth close to $38.4 million, accounting for 0.2% of its total 13F portfolio. The second largest stake is held by Visium Asset Management, led by Jacob Gottlieb, holding a $19.9 million position; 0.3% of its 13F portfolio is allocated to the stock. Some other professional money managers with similar optimism contain Tiger Management, Israel Englander’s Millennium Management, and Renaissance Technologies.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.